Competition heats up in hidradenitis suppurativa

With a new therapy under review and readouts coming this year from at least 11 late-stage molecules, competition is heating up in the as-yet underserved indication of hidradenitis suppurativa.

For an inflammatory disease that by some estimates could have a prevalence as large as 160 million patients globally, little innovation has reached patients to date. The only approved therapy is TNFα inhibitor Humira adalimumab from AbbVie Inc. (NYSE:ABBV). Otherwise, patients receive off-label antibiotics and steroids that do not address the underlying pathophysiology of the disease...